JP2016518823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518823A5 JP2016518823A5 JP2016502985A JP2016502985A JP2016518823A5 JP 2016518823 A5 JP2016518823 A5 JP 2016518823A5 JP 2016502985 A JP2016502985 A JP 2016502985A JP 2016502985 A JP2016502985 A JP 2016502985A JP 2016518823 A5 JP2016518823 A5 JP 2016518823A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- mutein
- cells
- disease
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091006004 Fc-tagged proteins Proteins 0.000 claims 30
- 102000000588 Interleukin-2 Human genes 0.000 claims 24
- 108010002350 Interleukin-2 Proteins 0.000 claims 24
- 210000004027 cells Anatomy 0.000 claims 21
- 239000011886 peripheral blood Substances 0.000 claims 13
- 210000003289 regulatory T cell Anatomy 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 8
- 230000000366 juvenile Effects 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 5
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 5
- 201000004681 psoriasis Diseases 0.000 claims 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 5
- 206010018651 Graft versus host disease Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 201000010874 syndrome Diseases 0.000 claims 3
- 102100001249 ALB Human genes 0.000 claims 2
- 101710027066 ALB Proteins 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 2
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- 206010052737 Atopic disease Diseases 0.000 claims 2
- 210000001772 Blood Platelets Anatomy 0.000 claims 2
- 206010009839 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011401 Crohn's disease Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 102100015541 FCGR3A Human genes 0.000 claims 2
- 101710044656 FCGR3A Proteins 0.000 claims 2
- 101710044657 FCGR3B Proteins 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010025135 Lupus erythematosus Diseases 0.000 claims 2
- 210000004698 Lymphocytes Anatomy 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102100007544 NCAM1 Human genes 0.000 claims 2
- 101700077124 NCAM1 Proteins 0.000 claims 2
- 210000000440 Neutrophils Anatomy 0.000 claims 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000002574 Reactive Arthritis Diseases 0.000 claims 2
- 206010038294 Reiter's syndrome Diseases 0.000 claims 2
- 208000000995 Spontaneous Abortion Diseases 0.000 claims 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 210000002435 Tendons Anatomy 0.000 claims 2
- 229940050528 albumin Drugs 0.000 claims 2
- 230000036760 body temperature Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002147 killing Effects 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000004962 mammalian cells Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 201000006704 ulcerative colitis Diseases 0.000 claims 2
- ZDTNHRWWURISAA-UHFFFAOYSA-N 4',5'-dibromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Br)=C1OC1=C(Br)C(O)=CC=C21 ZDTNHRWWURISAA-UHFFFAOYSA-N 0.000 claims 1
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003230 Arteritis Diseases 0.000 claims 1
- 206010003284 Arthropathy Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 210000000941 Bile Anatomy 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000565118 Cordylophora caspia Species 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000006881 Esophagitis Diseases 0.000 claims 1
- 208000004526 Exfoliative Dermatitis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000009883 Joint Disease Diseases 0.000 claims 1
- 210000001503 Joints Anatomy 0.000 claims 1
- 208000003377 Juvenile-onset scleroderma Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 206010061529 Polyp Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 claims 1
- 206010040490 Sexually transmitted disease Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 208000005482 Systemic Juvenile Rheumatoid Arthritis Diseases 0.000 claims 1
- 206010043778 Thyroiditis Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 230000002917 arthritic Effects 0.000 claims 1
- 201000008804 arthropathy Diseases 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000003899 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000002481 myositis Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001185 psoriatic Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Claims (49)
- Ｖ９１Ｋ置換と、配列番号１に記載のアミノ酸配列と少なくとも９０％同一のアミノ酸配列とを含み、前記ＩＬ−２ムテインは、制御性Ｔ細胞を選択的に刺激する、ヒトインターロイキン−２（ＩＬ−２）ムテイン。
- １２５位はアラニンである、請求項１に記載のヒトＩＬ−２ムテイン。
- １２５位はシステインである、請求項１に記載のヒトＩＬ−２ムテイン。
- Ｆｃ及び請求項１〜３のいずれかに記載のヒトＩＬ−２ムテインを含む、Ｆｃ融合タンパク質。
- 前記Ｆｃは、ヒトＩｇＧ１ Ｆｃである、請求項４に記載のＦｃ融合タンパク質。
- 前記ヒトＩｇＧ１ Ｆｃは、前記Ｆｃのエフェクター機能を変化させる１つ以上の変異を含む、請求項５に記載のＦｃ融合タンパク質。
- 前記ヒトＩｇＧ１は、Ｎ２９７に置換を含む、請求項６に記載のＦｃ融合タンパク質。
- Ｎ２９７の前記置換はＮ２９７Ｇである、請求項７に記載のＦｃ融合タンパク質。
- 前記ヒトＩｇＧ ＦｃのＣ末端リジンの置換または欠失を含む、請求項５〜８のいずれかに記載のＦｃ融合タンパク質。
- 前記ヒトＩｇＧ Ｆｃの前記Ｃ末端リジンが欠失される、請求項９に記載のＦｃ融合タンパク質。
- リンカーが、前記タンパク質のＦｃとヒトＩＬ−２ムテイン部分とを接続する、請求項４〜１０のいずれかに記載のＦｃ融合タンパク質。
- 前記リンカーは、ＧＧＧＧＳ（配列番号５）、ＧＧＮＧＴ、または（配列番号６）、及びＹＧＮＧＴ（配列番号７）である、請求項１１に記載のＦｃ融合タンパク質。
- 前記リンカーはＧＧＧＧＳ（配列番号５）である、請求項１２に記載のＦｃ融合タンパク質。
- 前記ＩＬ−２ムテインは、哺乳動物細胞内で発現させた時に前記Ｆｃ融合タンパク質のグリコシル化を変化させるアミノ酸の付加、置換、または欠失をさらに含む、請求項４〜１３のいずれかに記載のＦｃ融合タンパク質。
- 前記ＩＬ−２ムテインは、Ｔ３置換を含む、請求項１４に記載のＦｃ融合タンパク質。
- 前記ＩＬ−２ムテインは、Ｔ３ＮまたはＴ３Ａ置換を含む、請求項１５に記載のＦｃ融合タンパク質。
- 前記ＩＬ−２ムテインは、Ｔ３Ｎ置換を含む、請求項１６に記載のＦｃ融合タンパク質。
- 前記ＩＬ−２ムテインは、Ｓ５変異をさらに含む、請求項１７に記載のＦｃ融合タンパク質。
- 前記ＩＬ−２ムテインは、Ｓ５Ｔ変異をさらに含む、請求項１８に記載のＦｃ融合タンパク質。
- 前記Ｆｃ融合タンパク質は、Ｆｃ二量体を含む、請求項４から１９のいずれかに記載のＦｃ融合タンパク質。
- 前記Ｆｃ融合タンパク質は、２つのＩＬ−２ムテインを含む、請求項２０に記載のＦｃ融合タンパク質。
- 前記Ｆｃ融合タンパク質は、単一のＩＬ−２ムテインを含む、請求項２０に記載のＦｃ融合タンパク質。
- 請求項１〜３のいずれかに記載のヒトＩＬ−２ムテインをコードする、単離された核酸。
- 請求項４〜２２のいずれかに記載のＦｃ融合タンパク質をコードする、単離された核酸。
- 抗体の前記Ｆｃ部分及び前記ヒトＩＬ−２ムテインは、単一のオープンリーディングフレーム内でコードされる、請求項２４に記載の単離された核酸。
- プロモーターに作動可能に連結された請求項２３〜２５のいずれかに記載の前記単離された核酸を含む、発現ベクター。
- 請求項２３〜２５のいずれかに記載の単離された核酸を含む、宿主細胞。
- 前記単離された核酸は、プロモーターに作動可能に連結される、請求項２７に記載の宿主細胞。
- 前記宿主細胞は、原核細胞である、請求項２７または２８に記載の宿主細胞。
- 前記宿主細胞は、大腸菌である、請求項２９に記載の宿主細胞。
- 前記宿主細胞は、真核細胞である、請求項２７または２８に記載の宿主細胞。
- 前記宿主細胞は、哺乳動物細胞である、請求項３１に記載の宿主細胞。
- 前記宿主細胞は、チャイニーズハムスター卵巣（ＣＨＯ）細胞株である、請求項３２に記載の宿主細胞。
- ヒトＩＬ−２ムテインを作製する方法であって、前記プロモーターが発現される条件下で請求項２８〜３３のいずれかに記載の宿主細胞を培養することと、前記培養物から前記ヒトＩＬ−２ムテインを回収することと、を含む、方法。
- Ｆｃ融合タンパク質を作製する方法であって、前記プロモーターが発現される条件下で請求項２８〜３３のいずれかに記載の宿主細胞を培養することと、前記培養物から前記Ｆｃ融合タンパク質を回収することと、を含む、方法。
- Ｔ細胞の集団を、有効量の請求項１〜３のいずれかに記載のヒトＩＬ−２ムテインまたは請求項４〜２２のいずれかに記載のＦｃ融合タンパク質と接触させることを含む、
Ｔ細胞の集団内の非制御性Ｔ細胞に対する制御性Ｔ細胞（Ｔｒｅｇ）の比率を増加させる、
対象の末梢血中の非制御性Ｔ細胞に対する制御性Ｔ細胞（Ｔｒｅｇ）の比率を増加させる、または
対象の末梢血中のナチュラルキラー（ＮＫ）細胞に対する制御性Ｔ細胞（Ｔｒｅｇ）の比率を増加させる、方法。 - ＣＤ３＋ＦｏｘＰ３−に対するＣＤ３＋ＦｏｘＰ３＋細胞の比率が増加する、請求項３６に記載の方法。
- ＣＤ３＋ＦｏｘＰ３−に対するＣＤ３＋ＦｏｘＰ３＋細胞の比率は、少なくとも５０％増加する、請求項３７に記載の方法。
- 有効量の請求項１〜３のいずれかに記載のヒトＩＬ−２ムテインまたは請求項４〜２２のいずれかに記載のＦｃ融合タンパク質を投与することを含む、対象の末梢血中のナチュラルキラー（ＮＫ）細胞に対する制御性Ｔ細胞（Ｔｒｅｇ）の比率を増加させる方法。
- ＣＤ５６及び／またはＣＤ１６を発現するＣＤ３−ＣＤ１９−リンパ球に対するＣＤ３＋ＦｏｘＰ３＋細胞の比率が増加する、請求項３９に記載の方法。
- ＣＤ５６及び／またはＣＤ１６を発現するＣＤ３−ＣＤ１９−リンパ球に対するＣＤ３＋ＦｏｘＰ３＋細胞の比率は、少なくとも５０％増加する、請求項４０に記載の方法。
- 前記対象に治療有効量の請求項１〜３のいずれかに記載のＩＬ−２ムテインまたは請求項４〜２２のいずれかに記載のＦｃ融合タンパク質を投与することを含む、炎症性疾患または自己免疫性疾患に罹患する患者を治療する方法。
- 請求項４２に記載の炎症性疾患または自己免疫性疾患に罹患する患者を治療する方法であって、投与が、前記疾患の少なくとも１つの症状の軽減をもたらす、方法。
- 対象の末梢血中の非制御性Ｔ細胞に対する制御性Ｔ細胞（Ｔｒｅｇ）の比率は、投与後に増加する、請求項４３に記載の方法。
- 対象の末梢血中の非制御性Ｔ細胞に対する制御性Ｔ細胞（Ｔｒｅｇ）の比率は、投与後も本質的に同じままである、請求項４３に記載の方法。
- 前記炎症性疾患または自己免疫性疾患は、炎症、アトピー性疾患、腫瘍随伴性自己免疫疾患、軟骨炎症、関節炎、関節リウマチ、若年性関節炎、若年性関節リウマチ、少関節型若年性関節リウマチ、多関節型若年性関節リウマチ、全身型若年性関節リウマチ、若年性強直性脊椎炎、若年性腸炎性関節炎、若年性反応性関節炎、若年性ライター症候群、ＳＥＡ症候群（血清陰性、腱付着部症、関節症症候群）、若年性皮膚筋炎、若年性乾癬性関節炎、若年性強皮症、若年性全身性エリテマトーデス、若年性血管炎、少関節型関節リウマチ、多関節型関節リウマチ、全身型関節リウマチ、強直性脊椎炎、腸炎性関節炎、反応性関節炎、ライター症候群、ＳＥＡ症候群（血清陰性、腱付着部症、関節症症候群）、皮膚筋炎、乾癬性関節炎、強皮症、血管炎、筋炎、多発性筋炎、皮膚筋炎、結節性多発動脈炎、ウェゲナー肉芽腫症、動脈炎、リウマチ性多発筋痛症、サルコイドーシス、硬化症、原発性胆汁性硬化症、硬化性胆管炎、シェーグレン症候群、乾癬、プラーク乾癬、滴状乾癬、逆性乾癬、膿胞性乾癬、乾癬性紅皮症、皮膚炎、アトピー性皮膚炎、粥状動脈硬化、狼瘡、スティル病、全身性エリテマトーデス（ＳＬＥ）、重症筋無力症、炎症性腸疾患（ＩＢＤ）、クローン病、潰瘍性大腸炎、セリアック病、多発性硬化症（ＭＳ）、喘息、ＣＯＰＤ、副鼻腔炎、ポリープを伴う副鼻腔炎、好酸球性食道炎、好酸球性気管支炎、ギラン−バレー疾患、Ｉ型糖尿病、甲状腺炎（たとえばグレーブス病）、アジソン病、レイノー現象、自己免疫性肝炎、移植片対宿主病（ＧＶＨＤ）、移植拒絶反応、腎障害、Ｃ型肝炎誘発性血管炎および自然流産からなる群から選択される、請求項４２〜４５のいずれかに記載の方法。
- 疾患が、ループス、移植片対宿主病（ＧＶＨＤ）、Ｃ型肝炎誘発性血管炎、全身性エリテマトーデス（ＳＬＥ）、関節リウマチ、乾癬、クローン病、潰瘍性大腸炎、セリアック病、多発性硬化症（ＭＳ）、Ｉ型糖尿病、自然流産、アトピー性疾患または炎症性腸疾患である、請求項４６に記載の方法。
- 請求項１に記載のヒトインターロイキン−２（ＩＬ−２）ムテインまたは請求項４に記載のＦｃ融合タンパク質を用いた治療に対する対象の反応を監視する方法であって、前記対象における変化を検出することを含み、前記変化は、
ａ）体温の上昇、
ｂ）前記対象の末梢血中のＣＲＰの上昇、
ｃ）前記対象の末梢血中の血小板の減少、
ｄ）前記対象の末梢血中の好中球の減少、または
ｅ）前記対象の末梢血中のアルブミンの減少であり、
前記変化が検出された後、前記治療は、中止されるか、一時中断されるか、投与頻度が減少されるか、または投薬量が減少される、方法。 - 前記変化は、
ａ）少なくとも０．５℃の体温の上昇、
ｂ）少なくとも０．２ｍｇ／ｍＬの前記対象の末梢血中のＣＲＰの上昇、
ｃ）少なくとも０．８倍の前記対象の末梢血中の血小板の減少、
ｄ）少なくとも０．８倍の前記対象の末梢血中の好中球の減少、または
ｅ）少なくとも０．４倍の前記対象の末梢血中のアルブミンの減少を含む、請求項４８に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784669P | 2013-03-14 | 2013-03-14 | |
| US61/784,669 | 2013-03-14 | ||
| PCT/US2014/029111 WO2014153111A2 (en) | 2013-03-14 | 2014-03-14 | Interleukin-2 muteins for the expansion of t-regulatory cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228769A Division JP2019058182A (ja) | 2013-03-14 | 2018-12-06 | 制御性ｔ細胞の増殖のためのインターロイキン−２ムテイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518823A JP2016518823A (ja) | 2016-06-30 |
| JP2016518823A5 true JP2016518823A5 (ja) | 2017-04-20 |
| JP6450365B2 JP6450365B2 (ja) | 2019-01-09 |
Family
ID=50680166
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502985A Active JP6450365B2 (ja) | 2013-03-14 | 2014-03-14 | 制御性ｔ細胞の増殖のためのインターロイキン−２ムテイン |
| JP2016502936A Active JP6480409B2 (ja) | 2013-03-14 | 2014-03-14 | アグリコシル化Ｆｃ含有ポリペプチド |
| JP2018228769A Pending JP2019058182A (ja) | 2013-03-14 | 2018-12-06 | 制御性ｔ細胞の増殖のためのインターロイキン−２ムテイン |
| JP2020175778A Active JP7227951B2 (ja) | 2013-03-14 | 2020-10-20 | 制御性ｔ細胞の増殖のためのインターロイキン－２ムテイン |
| JP2023019024A Pending JP2023053148A (ja) | 2013-03-14 | 2023-02-10 | 制御性ｔ細胞の増殖のためのインターロイキン－２ムテイン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502936A Active JP6480409B2 (ja) | 2013-03-14 | 2014-03-14 | アグリコシル化Ｆｃ含有ポリペプチド |
| JP2018228769A Pending JP2019058182A (ja) | 2013-03-14 | 2018-12-06 | 制御性ｔ細胞の増殖のためのインターロイキン−２ムテイン |
| JP2020175778A Active JP7227951B2 (ja) | 2013-03-14 | 2020-10-20 | 制御性ｔ細胞の増殖のためのインターロイキン－２ムテイン |
| JP2023019024A Pending JP2023053148A (ja) | 2013-03-14 | 2023-02-10 | 制御性ｔ細胞の増殖のためのインターロイキン－２ムテイン |
Country Status (40)
| Country | Link |
|---|---|
| US (7) | US9546203B2 (ja) |
| EP (2) | EP2970441B1 (ja) |
| JP (5) | JP6450365B2 (ja) |
| KR (4) | KR20220101009A (ja) |
| CN (2) | CN105358570B (ja) |
| AP (1) | AP2015008737A0 (ja) |
| AR (1) | AR095541A1 (ja) |
| AU (2) | AU2014236316B2 (ja) |
| BR (1) | BR112015022440B1 (ja) |
| CA (3) | CA2905141A1 (ja) |
| CL (2) | CL2015002686A1 (ja) |
| CR (2) | CR20200004A (ja) |
| CY (2) | CY1121767T1 (ja) |
| DK (2) | DK2970441T3 (ja) |
| EA (2) | EA032863B1 (ja) |
| ES (2) | ES2720225T3 (ja) |
| HK (1) | HK1220695A1 (ja) |
| HR (2) | HRP20190970T1 (ja) |
| HU (2) | HUE043488T2 (ja) |
| IL (2) | IL241349B (ja) |
| JO (1) | JO3796B1 (ja) |
| LT (2) | LT2970423T (ja) |
| MA (2) | MA38477B1 (ja) |
| ME (2) | ME03482B (ja) |
| MX (2) | MX2015012890A (ja) |
| MY (2) | MY202248A (ja) |
| NZ (1) | NZ751148A (ja) |
| PE (1) | PE20151763A1 (ja) |
| PH (1) | PH12015502051A1 (ja) |
| PL (2) | PL2970441T3 (ja) |
| PT (2) | PT2970441T (ja) |
| RS (2) | RS58791B1 (ja) |
| SG (2) | SG11201507420UA (ja) |
| SI (2) | SI2970441T1 (ja) |
| TN (1) | TN2015000416A1 (ja) |
| TR (2) | TR201908362T4 (ja) |
| TW (3) | TWI709572B (ja) |
| UA (1) | UA119140C2 (ja) |
| UY (1) | UY35454A (ja) |
| WO (2) | WO2014153111A2 (ja) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9926366B2 (en) * | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| SG11201507429TA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| WO2014144632A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human pac1 antibodies |
| MA39250B1 (fr) | 2014-02-06 | 2018-09-28 | Hoffmann La Roche | Protéines hybrides de l'interleukine-2 et leurs utilisations |
| SG10202010158TA (en) * | 2014-07-21 | 2020-11-27 | Delinia Inc | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| SG11201700629TA (en) | 2014-08-11 | 2017-02-27 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3194435A1 (en) | 2014-09-15 | 2017-07-26 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
| US10793613B2 (en) | 2014-12-15 | 2020-10-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2016246152A1 (en) * | 2015-04-10 | 2017-11-02 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| UA126270C2 (uk) | 2015-04-10 | 2022-09-14 | Емджен Інк. | Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EP3390447A1 (en) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap antibodies and uses thereof |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| MA43955B1 (fr) * | 2016-02-03 | 2022-02-28 | Amgen Inc | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite |
| CN114716557A (zh) * | 2016-02-03 | 2022-07-08 | 安进研发（慕尼黑）股份有限公司 | Psma和cd3双特异性t细胞接合抗体构建体 |
| US11053293B2 (en) | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| CN107287273B (zh) * | 2016-03-31 | 2021-03-09 | 复旦大学附属妇产科医院 | 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途 |
| EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| KR20180133198A (ko) * | 2016-05-04 | 2018-12-13 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| EP3475413B1 (en) | 2016-06-22 | 2024-02-14 | David Klatzmann | Genetically modified t lymphocytes |
| WO2018027025A1 (en) * | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| WO2018106885A1 (en) | 2016-12-07 | 2018-06-14 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| WO2019112852A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| SG11202003114UA (en) | 2017-10-04 | 2020-05-28 | Amgen Inc | Transthyretin immunoglobulin fusions |
| SG11202003965VA (en) * | 2017-12-06 | 2020-06-29 | Pandion Therapeutics Inc | Il-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| JP2021506291A (ja) * | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたｉｌ−２ ｆｃ融合タンパク質 |
| WO2019131964A1 (ja) * | 2017-12-27 | 2019-07-04 | 協和発酵キリン株式会社 | Ｉｌ－２改変体 |
| KR20200110362A (ko) * | 2018-01-12 | 2020-09-23 | 암젠 인크 | Pac1 항체 및 이의 용도 |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| MX2020009975A (es) * | 2018-03-28 | 2020-10-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso. |
| US20210127649A1 (en) | 2018-06-07 | 2021-05-06 | Korea Research Institute Of Bioscience And Biotechnology | Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| KR20210038548A (ko) | 2018-06-22 | 2021-04-07 | 큐진 인크. | 사이토카인-기반 생체활성 약물 및 이의 사용 방법 |
| SG11202013138RA (en) | 2018-07-02 | 2021-01-28 | Amgen Inc | Anti-steap1 antigen-binding protein |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| AU2019370339A1 (en) * | 2018-11-01 | 2021-06-10 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
| WO2020163782A2 (en) | 2019-02-08 | 2020-08-13 | The Uab Research Foundation | Immunotherapy for the treatment and prevention of inflammatory bowel disease |
| KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
| CN113661175A (zh) | 2019-02-15 | 2021-11-16 | 整体分子公司 | 包含共同轻链的抗体及其用途 |
| EP3946424A1 (en) | 2019-03-29 | 2022-02-09 | Institut Curie | Interleukin-2 variants with modified biological activity |
| CN111944036A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| JP2022535060A (ja) | 2019-06-07 | 2022-08-04 | アムジエン・インコーポレーテツド | 選択的に切断可能なリンカーを有する二重特異性結合構築物 |
| JP2022540089A (ja) | 2019-07-08 | 2022-09-14 | アムジエン・インコーポレーテツド | 多特異性トランスサイレチン免疫グロブリン融合物 |
| CN114450298A (zh) * | 2019-07-26 | 2022-05-06 | 威特拉公司 | 白介素-2制剂及其用途 |
| MX2022001866A (es) * | 2019-08-13 | 2022-03-11 | Amgen Inc | Muteinas de interleucina-2 para la expansion de celulas t reguladoras. |
| TW202124425A (zh) | 2019-09-13 | 2021-07-01 | 日商協和麒麟股份有限公司 | DcR3改型體 |
| CN114829585A (zh) * | 2019-11-20 | 2022-07-29 | 吉爱希公司 | 用于培养t细胞的组合物及使用其来培养t细胞的方法 |
| CN114929249A (zh) * | 2019-11-29 | 2022-08-19 | Nkmax有限公司 | 产生自然杀伤细胞及其组合物的方法 |
| JP2023505590A (ja) | 2019-12-12 | 2023-02-09 | イルトゥー・ファルマ | インターロイキン２キメラ構築物 |
| CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
| MX2022007754A (es) | 2019-12-20 | 2022-07-19 | Regeneron Pharma | Nuevos agonistas de il2 y metodos de uso de estos. |
| KR102653906B1 (ko) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
| CA3171795A1 (en) * | 2020-04-06 | 2021-10-14 | Jintang DU | Modular synthetic receptors and methods of use |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
| US20230226203A1 (en) * | 2020-06-18 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| CN112048018B (zh) * | 2020-08-31 | 2021-10-08 | 南方医科大学 | 一种嵌合t细胞生长因子及其应用 |
| KR20230097094A (ko) | 2020-10-29 | 2023-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 질환의 치료를 위한 융합 단백질 |
| EP4255931A1 (en) | 2020-12-03 | 2023-10-11 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| WO2022120224A1 (en) * | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| IL308733A (en) | 2021-05-27 | 2024-01-01 | Sanofi Sa | Fc variant with increased affinity for Fc receptors and improved thermal stability |
| CA3227990A1 (en) * | 2021-08-06 | 2023-02-09 | Amgen Inc. | Isolation of therapeutic protein |
| WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
| WO2023061005A1 (zh) * | 2021-10-14 | 2023-04-20 | 徕特康(苏州)生物制药有限公司 | 新型抗体-细胞因子融合蛋白及其制备方法和用途 |
| TW202323281A (zh) | 2021-10-14 | 2023-06-16 | 美商泰尼歐生物公司 | 間皮素結合蛋白及其用途 |
| WO2023102463A1 (en) * | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2023148397A1 (en) | 2022-02-07 | 2023-08-10 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
| WO2023164476A2 (en) * | 2022-02-22 | 2023-08-31 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
| WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0351410A1 (en) | 1987-03-18 | 1990-01-24 | 3i RESEARCH EXPLOITATION LIMITED | Complement-binding peptide |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| CA2062582C (en) | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| FR2752462B1 (fr) | 1996-08-14 | 1998-10-23 | Essilor Int | Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| WO2000018938A1 (en) | 1998-09-29 | 2000-04-06 | Pioneer Hi-Bred International, Inc. | Mar/sar elements flanking rsyn7-driven construct |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
| RU2006135112A (ru) | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
| SI1877090T1 (sl) * | 2005-05-06 | 2014-12-31 | Providence Health System | Trimerni fuzijski protein OY40-imunoglobulina in postopki uporabe |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
| CN101627054A (zh) * | 2005-07-11 | 2010-01-13 | 马克罗基因公司 | 用人源化抗cd16a抗体治疗自身免疫疾病的方法 |
| GB0623539D0 (en) | 2006-11-24 | 2007-01-03 | Avidex Ltd | Polypeptides |
| CN101951940A (zh) | 2007-03-15 | 2011-01-19 | 比奥根艾迪克Ma公司 | 自身免疫病的治疗 |
| US20090016935A1 (en) | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CA2749539C (en) | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
| US20120100140A1 (en) * | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| JP2013511281A (ja) | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Ｆｃ |
| KR20120107122A (ko) * | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| KR102099462B1 (ko) | 2010-11-30 | 2020-04-10 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
| DK3489255T3 (da) * | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Muterede interleukin-2-polypeptider |
| ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| JP6419068B2 (ja) | 2012-05-21 | 2018-11-07 | ジェネンテック， インコーポレイテッド | 血液脳関門輸送の安全性を改善するための方法 |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| SG11201507429TA (en) * | 2013-03-15 | 2015-10-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-03-13 US US14/209,914 patent/US9546203B2/en active Active
- 2014-03-13 US US14/209,699 patent/US9580486B2/en active Active
- 2014-03-14 AU AU2014236316A patent/AU2014236316B2/en active Active
- 2014-03-14 AP AP2015008737A patent/AP2015008737A0/xx unknown
- 2014-03-14 JP JP2016502985A patent/JP6450365B2/ja active Active
- 2014-03-14 EA EA201591731A patent/EA032863B1/ru not_active IP Right Cessation
- 2014-03-14 LT LTEP14722463.8T patent/LT2970423T/lt unknown
- 2014-03-14 SI SI201431137T patent/SI2970441T1/sl unknown
- 2014-03-14 UY UY0001035454A patent/UY35454A/es active IP Right Grant
- 2014-03-14 KR KR1020227022964A patent/KR20220101009A/ko not_active Application Discontinuation
- 2014-03-14 HU HUE14769541A patent/HUE043488T2/hu unknown
- 2014-03-14 PT PT14769541T patent/PT2970441T/pt unknown
- 2014-03-14 MX MX2015012890A patent/MX2015012890A/es active IP Right Grant
- 2014-03-14 TW TW108117705A patent/TWI709572B/zh active
- 2014-03-14 PT PT14722463T patent/PT2970423T/pt unknown
- 2014-03-14 WO PCT/US2014/029111 patent/WO2014153111A2/en active Application Filing
- 2014-03-14 MY MYPI2018002567A patent/MY202248A/en unknown
- 2014-03-14 TR TR2019/08362T patent/TR201908362T4/tr unknown
- 2014-03-14 CA CA2905141A patent/CA2905141A1/en active Pending
- 2014-03-14 MX MX2015012912A patent/MX366854B/es active IP Right Grant
- 2014-03-14 EP EP14769541.5A patent/EP2970441B1/en active Active
- 2014-03-14 KR KR1020157027041A patent/KR102418771B1/ko active IP Right Grant
- 2014-03-14 LT LTEP14769541.5T patent/LT2970441T/lt unknown
- 2014-03-14 TW TW103109295A patent/TWI687435B/zh active
- 2014-03-14 MY MYPI2015002295A patent/MY172991A/en unknown
- 2014-03-14 SG SG11201507420UA patent/SG11201507420UA/en unknown
- 2014-03-14 PL PL14769541T patent/PL2970441T3/pl unknown
- 2014-03-14 EP EP14722463.8A patent/EP2970423B1/en active Active
- 2014-03-14 PL PL14722463T patent/PL2970423T3/pl unknown
- 2014-03-14 WO PCT/US2014/028913 patent/WO2014153063A1/en active Application Filing
- 2014-03-14 TW TW109121895A patent/TWI784288B/zh active
- 2014-03-14 TR TR2019/10802T patent/TR201910802T4/tr unknown
- 2014-03-14 CN CN201480027384.4A patent/CN105358570B/zh active Active
- 2014-03-14 PE PE2015002007A patent/PE20151763A1/es active IP Right Grant
- 2014-03-14 CA CA3149348A patent/CA3149348C/en active Active
- 2014-03-14 RS RS20190622A patent/RS58791B1/sr unknown
- 2014-03-14 CA CA2906708A patent/CA2906708C/en active Active
- 2014-03-14 ME MEP-2019-148A patent/ME03482B/me unknown
- 2014-03-14 NZ NZ751148A patent/NZ751148A/en unknown
- 2014-03-14 DK DK14769541.5T patent/DK2970441T3/da active
- 2014-03-14 CR CR20200004A patent/CR20200004A/es unknown
- 2014-03-14 JP JP2016502936A patent/JP6480409B2/ja active Active
- 2014-03-14 HU HUE14722463 patent/HUE044321T2/hu unknown
- 2014-03-14 EA EA201591766A patent/EA034326B1/ru not_active IP Right Cessation
- 2014-03-14 ES ES14769541T patent/ES2720225T3/es active Active
- 2014-03-14 ME MEP-2019-162A patent/ME03437B/me unknown
- 2014-03-14 SG SG11201507574VA patent/SG11201507574VA/en unknown
- 2014-03-14 SI SI201431252T patent/SI2970423T1/sl unknown
- 2014-03-14 MA MA38477A patent/MA38477B1/fr unknown
- 2014-03-14 RS RS20190688A patent/RS58854B1/sr unknown
- 2014-03-14 AR ARP140101154A patent/AR095541A1/es unknown
- 2014-03-14 KR KR1020157027977A patent/KR102219124B1/ko active IP Right Grant
- 2014-03-14 AU AU2014236281A patent/AU2014236281B2/en active Active
- 2014-03-14 CN CN201480014913.7A patent/CN105143253B/zh active Active
- 2014-03-14 ES ES14722463T patent/ES2737598T3/es active Active
- 2014-03-14 BR BR112015022440-7A patent/BR112015022440B1/pt active IP Right Grant
- 2014-03-14 DK DK14722463.8T patent/DK2970423T3/da active
- 2014-03-14 UA UAA201509641A patent/UA119140C2/uk unknown
- 2014-03-14 KR KR1020237037995A patent/KR20230157526A/ko not_active Application Discontinuation
- 2014-03-16 JO JOP/2014/0119A patent/JO3796B1/ar active
-
2015
- 2015-09-09 IL IL241349A patent/IL241349B/en active IP Right Grant
- 2015-09-11 TN TN2015000416A patent/TN2015000416A1/en unknown
- 2015-09-11 PH PH12015502051A patent/PH12015502051A1/en unknown
- 2015-09-14 CL CL2015002686A patent/CL2015002686A1/es unknown
- 2015-09-14 CL CL2015002669A patent/CL2015002669A1/es unknown
- 2015-09-16 IL IL241622A patent/IL241622B/en active IP Right Grant
- 2015-10-09 MA MA49207A patent/MA49207B1/fr unknown
- 2015-10-14 CR CR20150557A patent/CR20150557A/es unknown
-
2016
- 2016-07-20 HK HK16108640.9A patent/HK1220695A1/zh unknown
- 2016-12-06 US US15/371,131 patent/US10093711B2/en active Active
-
2017
- 2017-01-17 US US15/408,281 patent/US9932380B2/en active Active
-
2018
- 2018-02-09 US US15/893,451 patent/US10562950B2/en active Active
- 2018-02-21 US US15/901,705 patent/US10829535B2/en active Active
- 2018-12-06 JP JP2018228769A patent/JP2019058182A/ja active Pending
-
2019
- 2019-05-24 CY CY20191100560T patent/CY1121767T1/el unknown
- 2019-05-28 HR HRP20190970TT patent/HRP20190970T1/hr unknown
- 2019-06-14 HR HRP20191075TT patent/HRP20191075T1/hr unknown
- 2019-07-22 CY CY20191100775T patent/CY1121823T1/el unknown
-
2020
- 2020-10-05 US US17/063,566 patent/US11976102B2/en active Active
- 2020-10-20 JP JP2020175778A patent/JP7227951B2/ja active Active
-
2023
- 2023-02-10 JP JP2023019024A patent/JP2023053148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518823A5 (ja) | ||
| HRP20191075T1 (hr) | Muteini interleukina-2 za ekspanziju t-regulatornih stanica | |
| JP6983787B2 (ja) | 自己免疫疾患の治療のために制御性ｔ細胞を選択的に活性化する分子 | |
| Bloch et al. | Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12Rβ1 | |
| KR102493543B1 (ko) | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 | |
| JP2018512151A5 (ja) | ||
| JP2019533443A (ja) | ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ−融合タンパク質 | |
| RU2020120145A (ru) | Частичные агонисты интерлейкина-2 | |
| KR102036399B1 (ko) | 단백질 발현용 재조합 박테리아 숙주 세포 | |
| Lee et al. | Molecular basis for the neutralization of tumor necrosis factor α by certolizumab pegol in the treatment of inflammatory autoimmune diseases | |
| CN104302309A (zh) | Ctla-4变体 | |
| JP2015524413A5 (ja) | ||
| JP2022521937A (ja) | ＮＫｐ３０に結合する抗体分子およびその使用 | |
| WO2015020193A1 (ja) | 新規抗ヒトｔｓｌｐ受容体抗体 | |
| CN115812077A (zh) | April和baff抑制性免疫调节蛋白及其使用方法 | |
| JP2015511599A5 (ja) | ||
| CN111763256A (zh) | 鸡cr2基因的克隆、蛋白的表达和纯化及其多克隆抗体的制备 | |
| Ware | Protein therapeutics targeted at the TNF superfamily | |
| JP2017508446A (ja) | 二機能性融合タンパク質及びその製造方法並びに使用 | |
| CN101407546B (zh) | 全人源抗人肿瘤坏死因子-α单链抗体 | |
| EP3946451A1 (en) | Fibroblast activation protein binding agents and use thereof | |
| JP6137169B2 (ja) | 新規抗ヒトｉｌ−２３受容体抗体 | |
| CN105504057B (zh) | 抗汉滩病毒鼠/人嵌合抗体及其应用 | |
| WO2020224529A1 (zh) | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 | |
| JP2023539645A (ja) | Ｎｋｐ３０に結合する抗体分子およびその使用 |